However, topo IIβ was significantly associated with several factors that have been associated with favorable outcomes in AML, such as younger age, low CD4, CD14, CD16, CD54, CD11b, and HLA-DR, as well as with unfavorable factors, high peripheral and marrow blast percentage and increased CD7 expression. This evidence concerns the gene CD14 and acute myeloid leukemia.